Lilac Corp: Innovating Futures with Elegance
Lilac Corp specializes in natural treatments against viruses. Our treatments were tested in clinical studies and proven to be 100% safe and effective. You can find the medical papers that report these studies on Google. Our treatments work against many viruses, including HPV (human papillomavirus), HSV (herpes virus), CMV, EBV, and others. These viruses are known to cause many diseases, such as cancer, heart disease, diabetes, Alzheimer’s disease, and Parkinson’s disease and many others. Currently, we are offering three products: Gene-Eden-VIR (against viruses that cause major diseases), Novirin (against viruses that cause major diseases) the difference between the two products is that Novirin has higher quality, more expensive ingredients and Nolopecia (against hair loss). Lilac Corp specializes in natural treatments developed using an Artificial Intelligence (AI) computer program called Computer Intuition. The program was designed to turn scientists into geniuses. A clinical study showed that Gene-Eden-VIR/Novirin clears the human papillomavirus (HPV). The clinical study was conducted by Dr. Hanan Polansky, Dr. Edan Itzkovitz, and Adrian Javaherian from the Center for the Biology of Chronic Disease (CBCD). The study was published in the leading medical journal Drug Design, Development and Therapy. Another clinical study showed that Gene-Eden-VIR/Novirin decrease and even stop the herpes outbreaks. This study also showed that Gene-Eden-VIR/Novirin is safer and more effective than the three leading drugs used in the treatment of genital herpes. Gene-Eden-VIR/Novirin is a natural treatment that is also designed to help the immune system target the latent Epstein Barr Virus (EBV). A post marketing clinical study showed that Gene-Eden-VIR/Novirin decreased symptoms of an EBV infection. Nolopecia is a patented herbal treatment against hair loss for both men and women. Nolopecia was launched at the end of 2017. All of the studies published by PubMed and leading journals follow the FDA guidelines for clinical studies.